Indian Journal of Dermatology
THERAPEUTIC ROUND
Year
: 2022  |  Volume : 67  |  Issue : 5  |  Page : 568--572

Anti CD-6 monoclonal antibodies in the management of generalised pustular psoriasis


Mahendra M Kura, Anmol Sodhi, Avinash Sajgane, Ashish Karande 
 Department of Dermatology, Venereology and Leprosy, Grant Government Medical College, Sir JJ Group of Hospitals, Mumbai, Maharashtra, India

Correspondence Address:
Anmol Sodhi
Skin OPD 42, Main OPD Building, JJ Hospital, Byculla, Mumbai, Maharashtra - 400 008
India

Generalised pustular psoriasis (GPP) is an uncommon, severe, life-threatening variant of psoriasis requiring careful therapeutic approach. Conventional treatment modalities have unsatisfactory outcomes, poor side effect profiles and toxicities that have led to an emerging use of biological therapies. Itolizumab, an anti-CD-6 humanised monoclonal IgG1 antibody, is approved for the management of chronic plaque psoriasis in India. We share our experience of using this drug in three cases of GPP that were failing conventional therapies. Its upstream effect on co-stimulatory pathway in disease pathogenesis is the postulated mechanism. Our experience warrants further large-scale exploration of the role of itolizumab in the management of GPP, which would benefit this severely affected population of patients. Although the definite pathogenesis of GPP is unknown fully, molecules blocking CD-6, which plays a role in the interaction between T cells and antigen-presenting cells (APCs), are expected as new promising treatment options for GPP.


How to cite this article:
Kura MM, Sodhi A, Sajgane A, Karande A. Anti CD-6 monoclonal antibodies in the management of generalised pustular psoriasis.Indian J Dermatol 2022;67:568-572


How to cite this URL:
Kura MM, Sodhi A, Sajgane A, Karande A. Anti CD-6 monoclonal antibodies in the management of generalised pustular psoriasis. Indian J Dermatol [serial online] 2022 [cited 2023 Mar 29 ];67:568-572
Available from: https://www.e-ijd.org/article.asp?issn=0019-5154;year=2022;volume=67;issue=5;spage=568;epage=572;aulast=Kura;type=0